Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit

Vaccine

Volumn 12, Issue 8, 1994, Pages 731-735

  Oien, Nancee L ^a   Brideau, Roger J ^a   Walsh, Edward E ^b   Wathen, Michael W ^a  

^a PFIZER INC   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

mucosal route; parenteral route; Respiratory syncytial virus

Indexed keywords

ALUMINUM HYDROXIDE; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMAL; ANTIBODIES, VIRAL; CHIMERIC PROTEINS; CHOLERA TOXIN; FEMALE; GLYCOPROTEINS; IMMUNOGLOBULIN ISOTYPES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY SYSTEM; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0028175128     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)90224-0     Document Type: Article

References (29)

1. Respiratory syncytial virus infections, re-infections, and immunity
2. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus
3. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity
4. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live virus challenge
5. Administration of a highly attenuated, live respiratory syncytial vaccine to adults and children
6. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection
7. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein
8. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race, and sex
9. Risk of primary infection and reinfection with respiratory syncytial virus
10. Immunity to and frequency of reinfection with respiratory syncytial virus
11. Quantitative aspects of passive immunity to respiratory syncytial virus infection in cotton rats
12. Repeated infections with respiratory syncytial virus
13. Natural reinfection of adults by respiratory syncytial virus: possible relation to mild upper respiratory disease
14. Effect of serum and nasal neutralizing antibodies on bovine respiratory syncytial virus in calves
15. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness
16. Influence of immunological factors in respiratory syncytial virus disease of the lower respiratory tract
17. Local antibody production and respiratory syncytial virus infection in children with leukaemia
18. The mucosal immune system: from fundamental concepts to vaccine development
19. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice
20. Induction of an enteric lg-response against ovalbumin and stimulation of the response by cholera toxin and its B-subunit in mice
21. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination
22. Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination
23. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
24. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein using a baculovirus vector
25. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit
26. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus
27. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus
28. The role of lgA in local immune protection
29. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine